Emideltide (DSIP)
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Research / no approved-treatment claim
FDA identifies safety concerns or important evidence gaps. Research labeling is not permission for human use.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proponents claim DSIP may improve sleep or insomnia and reduce stress; it has also been proposed for pain and opioid withdrawal.
Its sleep-related name and investigational history are not proof of a reliable modern sleep or withdrawal treatment.
Evidence and source limits
Compounded drugs containing emideltide may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified safety-related information regarding emideltide for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.
This entry records a regulator safety assessment, not a treatment benefit or a clinical recommendation. A research-purpose-only label does not establish safety, FDA approval or permission to use a substance in people. No dosing, supplier or administration guidance is provided.
Original source: Emideltide (DSIP) ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.